Tag: secondary progressive MS
Propuesta pionera de un marco nuevo para describir los tipos de esclerosis múltiple
Moving away from traditional clinical categories of MS may lead to better, and more personalised treatments for MS.
Ganador del premio Young Investigator Award 2021
Dr Giacomo Boffa receives the 2021 Young Investigator Award on his project on using aHSCT in individuals with secondary progressive MS
First treatment for people with secondary progressive MS in Europe is approved
An important milestone for people with secondary progressive MS in Europe
¿Qué determina la conversión a EM secundaria progresiva?
An international study helps clinicians identify people who are at high risk of developing secondary progressive MS at an earlier stage.
Cladribine approved in US for people with active secondary progressive MS
FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS
Treatment licensed in US for people with active secondary progressive MS
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
El tratamiento con Natalizumab podría conservar la función de los miembros superiores en la EM progresiva secundaria
Results from a trial of natalizumab in secondary progressive MS suggest anti-inflammatory treatments could slow disability accumulation, even after significant function has been lost.
¿Los medicamentos antiinflamatorios retrasan la discapacidad en la esclerosis múltiple secundaria progresiva?
A new study recently published uses ‘real-world’ data to investigate the effects of disease modifying therapies on secondary progressive MS
Tipos de EM
MS comes in several forms, including clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS.